Mazdutide

Two receptors, one shared dream: a body that truly feels like yours. Mazdutide enters the multi-agonist category with its own distinct signature.

Instead of GIP, the second receptor here is glucagon — an energy expenditure signal alongside GLP-1, which calms appetite. Two forces, one direction.

And the numbers confirm it: in phase 3 GLORY-1, 610 people, the high dose reached −14.01% in 48 weeks, and almost one in two (49.5%) lost more than 15% of their body weight 1. A journey with real results.

The trial was done in Chinese adults — one population, a beginning. The molecule is still at an early stage of recognition outside China, although a network meta-analysis already ranks it squarely among the multi-agonists 2.

It's a new page in the same beautiful story — written carefully, without rushing.

Lyophilized and delicate, like every precious thing: fridge, darkness, rolled never shaken — and batch notes from day one, because care shows in the result.

Two receptors, not the ones you're thinking of. Forget GIP — here the second signal is glucagon, and it means something specific: energy expenditure, not just less hunger.

GLP-1 cuts your appetite. Glucagon raises your metabolic rate. Two mechanisms working in parallel, not one on top of the other.

The numbers, no frills. Phase 3 GLORY-1, 610 people, double-blind: −14.01% on the high dose in 48 weeks, vs +0.30% on placebo. Almost half (49.5%) passed 15% loss 1. And tolerability was clean: the discontinuation rate on the high dose was 0.5-1.5%, essentially the same as placebo (1.0%) 1.

The straight story: GLORY-1 was done in Chinese adults, one population. It doesn't yet have the approval older molecules have elsewhere, and there's no body composition data for it — we won't make it up for you.

New molecule, good numbers, less history behind it. You know what exists and what doesn't.

Lyophilized, fridge after reconstitution, never light, rolled not shaken. Keep batch notes — a new molecule means less collective handling experience.